-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On January 24, the pharmaceutical industry issued a number of positive and negative announcements.
Pharmaceutical companies such as Zhifei Bio and Aibo Medical expect to achieve a substantial increase in net profit in 2021, while Fuxiang Pharmaceutical predicts a decline of 80.
02%-86.
28%
.
Aibo Medical: It is expected that the net profit in 2021 will increase by 65.
70%-86.
42% year-on-year.
Aibo Medical released the 2021 annual performance forecast in the evening: It is expected that the net profit attributable to the owners of the parent company in 2021 will be 160 million to 180 million yuan, and Compared with the same period of last year (statutory disclosure data), it will increase by 65.
70% to 86.
42% year-on-year
.
Regarding the reasons for the growth in performance, Aibo Medical said that the increase in net profit during the reporting period was mainly due to the rapid growth in sales of the company's core products, intraocular lenses and orthokeratology lenses, and an increase in operating income
.
Among them, the sales volume of "Pu Nuo Ming" and other series of intraocular lenses is expected to increase by more than 40% compared with the same period of the previous year, and the sales of "Pu Nuo Tong" orthokeratology lenses are expected to increase by more than 110% compared with the same period of the previous year
.
Harbin Pharmaceutical Co.
, Ltd.
: It is expected that the net profit in 2021 will turn from loss to profit year-on-year.
Harbin Pharmaceutical Co.
, Ltd.
released the 2021 annual performance forecast
.
It is reported that during the reporting period, the company focused on target management, continued to sort out products, subdivide channels and terminal resources, and continuously improve the professional ability of the team.
The sales volume of the company's industrial sector increased by 26.
2% year-on-year, achieving a substantial increase in sales revenue; the variety structure was significantly higher than the same period.
The gross profit level increased by 8.
9% compared with the same period of last year, and the profit level in 2021 increased significantly compared with the same period of time
.
Zhifei Biology: Net profit in 2021 is expected to increase by 200%-220% year-on-year The 2021 annual performance forecast released by Zhifei Biology shows that the performance is expected to increase in the same direction
.
During the reporting period, the net profit attributable to shareholders of the listed company was 9.
903 billion yuan to 10.
564 billion yuan, an increase of 200%-220% over the same period of the previous year
.
During the reporting period, the company continued to focus on business development goals, increased investment in research and development, and introduced new products.
The sales of independent products and agency products continued to increase steadily.
The company's main business revenue, net profit and other important financial indicators will be higher than the same period last year.
larger growth
.
Xinhecheng: Net profit in 2021 is expected to increase by 15%-35% year-on-year.
Xinhecheng's 2021 performance forecast shows that performance is expected to rise in the same direction
.
During the reporting period, the net profit attributable to shareholders of the listed company was 4.
098 billion yuan – 4.
811 billion yuan, an increase of 15% – 35% over the same period of the previous year; basic earnings per share were 1.
59 yuan/share – 1.
87 yuan/share
.
Regarding the changes in performance, the company stated that during the reporting period, the sales price and sales volume of major products such as vitamin E and methionine increased compared with the same period of the previous year, resulting in a year-on-year increase in the net profit attributable to shareholders of the listed company during the reporting period
.
Guangji Pharmaceutical: Net profit in 2021 is expected to increase by 34%-61% year-on-year In the same period, it increased by 33.
96%-60.
76%
.
During the reporting period, the sales volume of the company's pharmaceutical-grade VB2 and VB6 products increased year-on-year.
In addition, the company's average interest-bearing liabilities decreased during the reporting period, resulting in a year-on-year decrease in interest expenses
.
Fuxiang Pharmaceutical: Net profit in 2021 is expected to drop by 80.
02%-86.
28% year-on-year Fuxiang Pharmaceutical expects that its performance in 2021 will decline in the same direction
.
During the reporting period, the net profit attributable to shareholders of the listed company was 43.
8 million yuan to 63.
8 million yuan, a decrease of 80.
02%-86.
28% over the same period of the previous year
.
Regarding the reasons for the decline in performance, Fuxiang Pharmaceutical stated that during the reporting period, the company’s procurement costs increased significantly due to the sharp rise in the prices of raw materials for the company’s main products; at the same time, affected by market demand and the epidemic, the sales and prices of some products decreased year-on-year.
, resulting in a decrease in profits
.
Pharmaceutical companies such as Zhifei Bio and Aibo Medical expect to achieve a substantial increase in net profit in 2021, while Fuxiang Pharmaceutical predicts a decline of 80.
02%-86.
28%
.
Aibo Medical: It is expected that the net profit in 2021 will increase by 65.
70%-86.
42% year-on-year.
Aibo Medical released the 2021 annual performance forecast in the evening: It is expected that the net profit attributable to the owners of the parent company in 2021 will be 160 million to 180 million yuan, and Compared with the same period of last year (statutory disclosure data), it will increase by 65.
70% to 86.
42% year-on-year
.
Regarding the reasons for the growth in performance, Aibo Medical said that the increase in net profit during the reporting period was mainly due to the rapid growth in sales of the company's core products, intraocular lenses and orthokeratology lenses, and an increase in operating income
.
Among them, the sales volume of "Pu Nuo Ming" and other series of intraocular lenses is expected to increase by more than 40% compared with the same period of the previous year, and the sales of "Pu Nuo Tong" orthokeratology lenses are expected to increase by more than 110% compared with the same period of the previous year
.
Harbin Pharmaceutical Co.
, Ltd.
: It is expected that the net profit in 2021 will turn from loss to profit year-on-year.
Harbin Pharmaceutical Co.
, Ltd.
released the 2021 annual performance forecast
.
It is reported that during the reporting period, the company focused on target management, continued to sort out products, subdivide channels and terminal resources, and continuously improve the professional ability of the team.
The sales volume of the company's industrial sector increased by 26.
2% year-on-year, achieving a substantial increase in sales revenue; the variety structure was significantly higher than the same period.
The gross profit level increased by 8.
9% compared with the same period of last year, and the profit level in 2021 increased significantly compared with the same period of time
.
Zhifei Biology: Net profit in 2021 is expected to increase by 200%-220% year-on-year The 2021 annual performance forecast released by Zhifei Biology shows that the performance is expected to increase in the same direction
.
During the reporting period, the net profit attributable to shareholders of the listed company was 9.
903 billion yuan to 10.
564 billion yuan, an increase of 200%-220% over the same period of the previous year
.
During the reporting period, the company continued to focus on business development goals, increased investment in research and development, and introduced new products.
The sales of independent products and agency products continued to increase steadily.
The company's main business revenue, net profit and other important financial indicators will be higher than the same period last year.
larger growth
.
Xinhecheng: Net profit in 2021 is expected to increase by 15%-35% year-on-year.
Xinhecheng's 2021 performance forecast shows that performance is expected to rise in the same direction
.
During the reporting period, the net profit attributable to shareholders of the listed company was 4.
098 billion yuan – 4.
811 billion yuan, an increase of 15% – 35% over the same period of the previous year; basic earnings per share were 1.
59 yuan/share – 1.
87 yuan/share
.
Regarding the changes in performance, the company stated that during the reporting period, the sales price and sales volume of major products such as vitamin E and methionine increased compared with the same period of the previous year, resulting in a year-on-year increase in the net profit attributable to shareholders of the listed company during the reporting period
.
Guangji Pharmaceutical: Net profit in 2021 is expected to increase by 34%-61% year-on-year In the same period, it increased by 33.
96%-60.
76%
.
During the reporting period, the sales volume of the company's pharmaceutical-grade VB2 and VB6 products increased year-on-year.
In addition, the company's average interest-bearing liabilities decreased during the reporting period, resulting in a year-on-year decrease in interest expenses
.
Fuxiang Pharmaceutical: Net profit in 2021 is expected to drop by 80.
02%-86.
28% year-on-year Fuxiang Pharmaceutical expects that its performance in 2021 will decline in the same direction
.
During the reporting period, the net profit attributable to shareholders of the listed company was 43.
8 million yuan to 63.
8 million yuan, a decrease of 80.
02%-86.
28% over the same period of the previous year
.
Regarding the reasons for the decline in performance, Fuxiang Pharmaceutical stated that during the reporting period, the company’s procurement costs increased significantly due to the sharp rise in the prices of raw materials for the company’s main products; at the same time, affected by market demand and the epidemic, the sales and prices of some products decreased year-on-year.
, resulting in a decrease in profits
.
